LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy
NCT: NCT07664189 · ENROLLING_BY_INVITATION
Brief Summary
The purpose of this pilot clinical trial is to evaluate whether a novel cardiac resynchronization strategy, called LOT-CRT, is more effective than standard physiological pacing alone (LBBAP) in patients with heart failure. This is a randomized, single-center, crossover pilot study involving 10 patients. All participants will receive a specialized pacemaker (CRT-P) with leads implanted in two specific areas: the Left Bundle Branch Area (LBBAP) and the Coronary Sinus (CS). Because of the crossover design, each patient will serve as their own control, receiving two different pacing configurations in a random order: Active Phase (LOT-CRT): Simultaneous pacing of the left bundle branch and the coronary sinus. Control Phase (LBBAP alone): Pacing only the left bundle branch area. Each treatment phase will last 6 months, for a total follow-up of 12 months per patient. By testing both strategies in the same patient, this study will help clinicians identify the most effective way to restore heart synchrony and improve clinical outcomes in patients with advanced heart failure and conduction delays.
Frequently Asked Questions
What is LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy?
LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy is a clinical trial registered under NCT07664189. Current status: ENROLLING_BY_INVITATION.
What is the status of NCT07664189?
The current status of NCT07664189 (LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy) is: ENROLLING_BY_INVITATION.
When did LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy start?
LBBP + CSP Versus LBBP Alone for Cardiac Resynchronization Therapy started on 2026-06-09.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.